Is LeMaitre Vascular (LMAT) Undervalued As Earnings Guidance And Dividend Reset Expectations?
LeMaitre Vascular (LMAT) just paired fresh quarterly results and a new dividend with updated guidance for 2026, giving investors a compact snapshot of its current earnings power and capital return plans.
LeMaitre Vascular’s recent mix of earnings, guidance and a fresh US$0.25 dividend comes after a softer stretch in the market. The share price is down 5.03% over the past week and 3.75% over 3 months, while the 1 year total shareholder return is down 10.65%. Even so, it still reflects a 53.45% gain over 3 years and 60.92% over 5 years, which suggests long term holders have been rewarded even as shorter term momentum has cooled around the latest updates.
Scan beyond LeMaitre Vascular and compare this mix of earnings, guidance and dividends with a curated 32 high quality undervalued stocks that pair solid financials with what could be more appealing entry points.
The recent pullback at LeMaitre Vascular could be read as a verdict on its latest earnings, or simply a reset in sentiment after a strong multi year run. Which story does the current valuation tell?
Most Popular Narrative: 21% Undervalued
On the analyst consensus Narrative on Simply Wall St, LeMaitre Vascular screens as undervalued, with a fair value of about $100.43 against the latest close of $79.29. That gap anchors the story around how much of the firm’s earnings potential is already reflected in the share price.
Disciplined capital allocation, with operating cash flow of roughly US$15m to US$16m per quarter, a cash and securities balance of about US$376m, ongoing sales force investment, and the recently announced US$100m share repurchase program and higher dividend, provides LeMaitre Vascular with multiple ways to convert its cash generation into future earnings per share growth.
See why 6 investors see LeMaitre Vascular as 21% undervalued.
Result: Fair Value of $100.43 (UNDERVALUED)
Still, that story only holds if LeMaitre Vascular keeps regulatory issues contained and avoids further guidance cuts that could unsettle expectations around its earnings power.
Find out about the key risks to this LeMaitre Vascular narrative.
Another View: What LeMaitre Vascular’s P/E Is Saying
While the Simply Wall St fair value model tags LeMaitre Vascular as undervalued, the market’s P/E tells a tougher story. LMAT trades on 28.6x earnings, above the US Medical Equipment industry on 26x and above its own fair ratio of 24.1x, which points to valuation risk if growth stumbles. So is the real opportunity already priced in, or just priced rich for now?
See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed messages on LeMaitre Vascular leave you torn between caution and optimism, let the data do the talking and consider acting while sentiment is still resetting. To see what investors are currently focused on, take a closer look at the 2 key rewards.
Looking for more LeMaitre Vascular sized ideas?
Do not stop with LeMaitre Vascular. Use the Simply Wall St Screener to widen your watchlist and pressure test whether this stock still earns a spot.
- Target resilience first and filter for companies that combine dependable balance sheets with solid fundamentals using the list of solid balance sheet and fundamentals (24 results).
- Spot potential mispricings early and compare LeMaitre Vascular with a curated 32 high quality undervalued stocks that already clear quality and valuation hurdles.
- Secure more predictable cash returns and build a watchlist around income ideas through a focused 6 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com